Abstract:604 Background: Immune checkpoint inhibitors (ICIs) are widely used to treat genitourinary cancers, particularly urothelial carcinoma (UC) and renal cell carcinoma (RCC). Infusion-related reactions (IRRs) have been reported in up to 20% of all patients treated with ICIs. However, the risk of IRRs varies with the type of ICI and the accurate incidence in genitourinary cancers remains unclear. We undertook a systematic review and meta-analysis to determine the incidence of IRRs in patients with genitourinary cancers treated with ICIs. Methods: We performed a systematic search of PubMed/MEDLINE, Embase, and Web of Science to identify phase 3 randomized clinical trials (RCTs) evaluating ICIs (cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], programmed cell death protein 1 [PD-1], and programmed death-ligand 1 [PD-L1] inhibitors) in patients with UC and RCC. The odds ratio [OR] of grade 1-5 and grade 3-5 IRRs was calculated and pooled by the random-effect model meta-analysis. Meta-analysis was performed based on study types as follows: 1) Studies with a design “ICI plus treatment A (including placebo/observation) vs. treatment A”, 2) Studies evaluating ICI monotherapy vs. chemotherapy in patients with UC, and 3) Studies assessing ICI plus vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) vs. sunitinib in patients with RCC. When IRRs were reported in studies evaluating oral VEGF-TKIs, IRRs were referred to as hypersensitivity or anaphylactic reactions, defined in each RCT. Results: We identified 12 RCTs with 10,001 participants for the meta-analysis, out of which one evaluated a CTLA-4 inhibitor while the others evaluated PD-1 or PD-L1 inhibitors. The addition of ICIs to other systemic therapies was associated with significantly higher rates of grade 1-5 IRRs (OR=2.90, 95% confidence interval [CI]: 1.16-7.29, p = 0.02) but not of grade 3-5 IRRs (OR=2.98, 95% CI: 0.64-13.74, p = 0.16). When compared to chemotherapy, PD-1 or PD-L1 inhibitor monotherapy was not associated with an increase in either grade 1-5 (OR=0.86, 95% CI: 0.25-2.95, p = 0.81) or grade 3-5 IRRs (OR=1.13, 95% CI: 0.07-18.19, p = 0.93) in patients with UC. When compared to sunitinib in patients with RCC, the combination of ICI plus VEGF-TKIs was not associated with an increase in either grade 1-5 (OR=5.43, 95% CI: 0.62-46.07, p = 0.13) or grade 3-5 IRRs (OR=3.49, 95% CI: 0.64-19.04, p = 0.15). Sensitivity analysis performed by removing studies evaluating avelumab did not alter the overall results (data will be presented). Conclusions: Compared to the previous standard of care without ICIs, therapies with ICIs were not associated with increased IRRs in genitourinary cancers. However, the addition of ICIs to other systemic therapies was associated with an increased incidence of IRRs. The latter merits further prospective evaluation and careful consideration while designing clinical trials.

Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Immune-related adverse events (irAEs) and the association with clinical outcomes in advanced genitourinary cancers treated with immunotherapy: A systematic review and meta-analysis.

Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world setting.

Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer

Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta -analysis

Immune-Related Adverse Events of Genitourinary Cancer Patients, a Retrospective Cohort Study

Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.

Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma

Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors

Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).

Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis

The Predictive Value of Systemic Immune-Inflammation Index on Bladder Recurrence on Upper Tract Urothelial Carcinoma Outcomes after Radical Nephroureterectomy

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors

Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis